Cytomedix (OTC:CMXI) touted a reimbursement win from the Centers for Medicare & Medicaid Services for plasma systems including its AutoloGel product.

The coverage decision includes Cytomedix’s platelet-rich plasma system for patients with chronic ulcers and wounds, under the Coverage with Evidence Development program, a CMS guidance policy that gathers data and public comments to include in coverage decisions.

"We are enthusiastic that Medicare beneficiaries will soon be treated with AutoloGel and look forward to this opportunity to improve the health outcomes of patients dealing with non-healing chronic wounds," CEO Martin Rosendale said in prepared remarks. "We recently received protocol approval under the Coverage with Evidence Development program, and detailed coding and payment instructions have now been issued to CMS’ regional contractors and fiscal intermediaries."

Cytomedix recently announced $27.5 million in financing for 2013.